At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,081 enrolled
Drug / intervention
Aripiprazole IM Depotdrug
Likely dose
Aripiprazole IM Depot 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Aug 11, 2008·Updated Nov 26, 2014
In Brief
A Phase 3 clinical trial evaluating Aripiprazole IM Depot for Schizophrenia. Completed, enrolled 1,081 participants across 214 sites in 28 countries.
Detailed Summary
To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesArgentina, Australia, Austria, Belgium, Bulgaria, Chile, Croatia, Estonia, Finland, France, Hungary, India, Malaysia, Mexico, Norway, Philippines, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, United States
CollaboratorsCovance
Timeline
Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2008
Enrollment StartDec 2008
Primary CompletionNov 2013
TodayJul 2026
First PostedAug 11, 2008
Enrollment StartDec 1, 2008
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 17.9 years ago
Interventions
Aripiprazole IM Depotdrug
300mg or 400mg